Pain Management Drugs Market Study 2019: Impressively growing Opportunities With Key Companies Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries, Eli Lilly and Company, Abbott Laboratories

CoherentMarketInsights.com Publish a New Market Research Report On –“ Agrochemicals Market 2019 Global Analysis By Key Players –Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories”.

In 2015, Depomed, Inc. acquired the U.S. rights to NUCYNTA (tapentadol), NUCYNTA ER (tapentadol) extended release tablets, and NUCYNTA (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. Tapentadol is available in tablet, solution, and extended release forms. Furthermore, the tablet and solution forms of NUCYNTA has three patents, out of which one expired in June 2017 and other two will expire in June 2025 and August 2029, respectively. Moreover, patent expiry of pain management drugs such as Oxycontin, Opana, Celebrex (2013 - 2014), and others are providing opportunity to market players for introducing new products in the pain management drugs market.

Moreover, introduction of novel drug delivery systems such as prefilled syringes and injectable dosage are offered by manufacturers such as Pfizer, Inc., which is expected to boost the market growth over the forecast period. Manufacturers offer wide range of products, which include generic as well as branded products in capsules and tablet forms. Also, some of the drugs are cost-effective alternative as compared to the pain therapies such as invasive approach and physiotherapy. These factors are further expected to boost the market growth over the forecast period.

The global pain management drugs market was valued at US$ 63,212.3 Mn in 2017 and is expected to witness a robust CAGR of 3.9% over the forecast period (2018 – 2026).

Access PDF Template Copy of this Report at:
https://www.coherentmarketinsights.com/insight/request-sample/1697

According to the American Academy of Pain Medicine, in 2011, around 1.8 billion people suffered from chronic pain. Moreover, the National Institutes of Health (NIH) estimates that one in 10 people in the U.S. suffer from chronic pain. According to a study published in the British Medical Journal in 2016, nearly one-third to half of the population in the U.K. suffers from chronic pain. Moreover, according to the NIH estimates published in 2015 by the American Pain Society, around 50 million people in the U.S. suffered from chronic pain. Moreover, rising prevalence of pain and increasing prevalence of diseases such as cancer and others are driving growth of the pain management drugs market. For instance, according to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S. and 609,640 people are expected to die from the disease.

However, side effects associated with the pain management drugs and addiction issues with the opioid medications are expected to hinder growth of the pain management drugs market over the forecast period.

Some major players operating in the pain management drugs market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.

Get Customized Report in your Inbox within 24 hours @
https://www.coherentmarketinsights.com/insight/request-customization/1697

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.